Physician profile
Michael C Desantis
NPI 1780610394
$10,433.17
in general payments reported to CMS, 2019-2025
60 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $1,329 · 2021: $1,312 · 2022: $1,736 · 2023: $1,234 · 2024: $1,406 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,072.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $976.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $935.22 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Amgen INC. | $844.79 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $798.10 | 2019-2025 | |
| Preventric Diagnostics, INC. | $568.96 | 2022 | |
| Novo Nordisk INC | $528.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $526.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $348.46 | 2019-2023 | Xarelto |
| Allergan, INC. | $320.50 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $293.00 | 2019-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.62 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $247.21 | 2019-2024 | Trintellix, Gattex |
| Astellas Pharma US INC | $184.26 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $173.49 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Desantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.